Lapatinib breast cancer targeted therapy price overview

Lapatinib, an innovative oral small molecule drug, is an epidermal growth factor tyrosine kinase inhibitor and has significant anti-tumor activity. It mainly acts on the ErbB-1 and ErbB-2 receptors, which play key roles in the occurrence and development of various tumors such as breast cancer.

In the field of breast cancer treatment, the emergence of lapatinib is of great significance. It is especially suitable for patients with advanced or metastatic breast cancer who overexpress HER2 (human epidermal growth factor receptor 2) and have experienced treatment with anthracyclines, paclitaxel, trastuzumab, etc. When used in combination with drugs such as capecitabine, lapatinib can significantly extend the progression-free survival of patients, bringing new treatment hope to these patients.

From the perspective of clinical pharmacology and pharmacokinetics, there are certain individual differences in the absorption of lapatinib, and the peak plasma concentration is usually reached about 4 hours after oral administration. The drug is metabolized primarily by the liver and is ultimately excreted in the feces. During treatment, lapatinib demonstrated good safety and tolerability. Although some patients may experience gastrointestinal discomfort such as nausea and diarrhea, these symptoms can usually be effectively relieved with appropriate supportive care.

In general, lapatinib, as a targeted therapy drug, with its unique mechanism of action and multi-faceted tumor inhibitory effect, provides an effective and relatively safe new treatment option for breast cancer patients, especially those who are resistant to traditional treatments. With its widespread use in clinical practice and continued research, we expect lapatinib to play a greater role in the treatment of breast cancer in the future.

Regarding price, the original research version of lapatinib is currently on the market at home and abroad. In China, the price of the original research version of lapatinib, which is 250mg*70 tablets, is about 6,000 yuan. In addition, it is understood that there are also generic versions of lapatinib on the market in India, Bangladesh and other places. The overseas price of the generic version of 30 tablets is approximately 600 to 900 yuan. If necessary, patients can consult with regular overseas medical consulting companies about purchasing generic versions of lapatinib.

xa0

Reference materials:https://www.nmpa.gov.cn/